Sartorius confirms FY 2026 sales growth outlook of 5%-9%

Reuters2026/07/23 05:15

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sartorius Stedim Biotech confirmed FY 2026 guidance for sales revenue growth of about 5% to 9% in constant currencies.
Underlying EBITDA margin still seen slightly above 30% for the group.
Guidance includes about 0.3 percentage points of growth from MATTEK; group expects net debt to underlying EBITDA slightly above 3x.
H1 2026 operational sales growth was 7.7%, with sales revenue of EUR 1.81 billion; underlying EBITDA margin rose to 30.3%.
Tariff-related customer compensation of EUR 26 million in Q2 weighed on reported growth; further refund applications total EUR 40 million, with EUR 14 million outstanding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sartorius confirms FY 2026 sales growth outlook of 5%-9%

You may also like

Crypto prices